201 related articles for article (PubMed ID: 34155064)
1. Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics.
Jiao J; Kwan SY; Sabotta CM; Tanaka H; Veillon L; Warmoes MO; Lorenzi PL; Wang Y; Wei P; Hawk ET; Almeda JL; McCormick JB; Fisher-Hoch SP; Beretta L
Cancer Epidemiol Biomarkers Prev; 2021 Sep; 30(9):1643-1651. PubMed ID: 34155064
[TBL] [Abstract][Full Text] [Related]
2. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.
Kodama K; Kawaguchi T; Hyogo H; Nakajima T; Ono M; Seike M; Takahashi H; Nozaki Y; Kawanaka M; Tanaka S; Imajo K; Sumida Y; Kamada Y; Fujii H; Seko Y; Takehara T; Itoh Y; Nakajima A; Masaki N; Torimura T; Saibara T; Karino Y; Chayama K; Tokushige K
J Gastroenterol Hepatol; 2019 Sep; 34(9):1626-1632. PubMed ID: 30668889
[TBL] [Abstract][Full Text] [Related]
3. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
Liu YL; Patman GL; Leathart JB; Piguet AC; Burt AD; Dufour JF; Day CP; Daly AK; Reeves HL; Anstee QM
J Hepatol; 2014 Jul; 61(1):75-81. PubMed ID: 24607626
[TBL] [Abstract][Full Text] [Related]
4. Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics.
Jiao J; Sanchez JI; Thompson EJ; Mao X; McCormick JB; Fisher-Hoch SP; Futreal PA; Zhang J; Beretta L
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299031
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease.
Cholankeril G; Kramer JR; Chu J; Yu X; Balakrishnan M; Li L; El-Serag HB; Kanwal F
J Hepatol; 2023 Mar; 78(3):493-500. PubMed ID: 36402450
[TBL] [Abstract][Full Text] [Related]
6. Fatty acid composition of the erythrocyte membrane and risk of hepatocellular carcinoma in cirrhotic patients.
Mouillot T; Rizk M; Pais de Barros JP; Gilloteau A; Busson A; Bernard-Chabert B; Thiefin G; Barraud H; Bronowicki JP; Richou C; Di Martino V; Doffoel M; Minello A; Latournerie M; Jouve JL; Brondel L; Brindisi MC; Petit JM; Hillon P; Cottet V;
Aliment Pharmacol Ther; 2020 Nov; 52(9):1503-1515. PubMed ID: 32780481
[TBL] [Abstract][Full Text] [Related]
7. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
Kanno M; Kawaguchi K; Honda M; Horii R; Takatori H; Shimakami T; Kitamura K; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
J Gastroenterol; 2019 Jun; 54(6):549-557. PubMed ID: 30707282
[TBL] [Abstract][Full Text] [Related]
8. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis.
Behari J; Gougol A; Wang R; Luu HN; Paragomi P; Yu YC; Molinari M; Chopra K; Malik SM; Geller D; Yuan JM
Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37395730
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease.
Song DS; Chang UI; Kang SG; Song SW; Yang JM
Gut Liver; 2019 Nov; 13(6):658-668. PubMed ID: 30970434
[TBL] [Abstract][Full Text] [Related]
10. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis.
Kimura T; Tanaka N; Fujimori N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Umemura T; Matsumoto A; Tanaka E
World J Gastroenterol; 2018 Apr; 24(13):1440-1450. PubMed ID: 29632425
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population.
Kogiso T; Sagawa T; Kodama K; Taniai M; Hashimoto E; Tokushige K
J Gastroenterol Hepatol; 2020 Sep; 35(9):1579-1589. PubMed ID: 31975453
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
[TBL] [Abstract][Full Text] [Related]
13. A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis.
Khan IM; Gjuka D; Jiao J; Song X; Wang Y; Wang J; Wei P; El-Serag HB; Marrero JA; Beretta L
Cancer Prev Res (Phila); 2021 Jun; 14(6):667-674. PubMed ID: 33685927
[TBL] [Abstract][Full Text] [Related]
14. Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma.
Enooku K; Nakagawa H; Fujiwara N; Kondo M; Minami T; Hoshida Y; Shibahara J; Tateishi R; Koike K
Sci Rep; 2019 Jul; 9(1):10663. PubMed ID: 31337855
[TBL] [Abstract][Full Text] [Related]
15. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
[TBL] [Abstract][Full Text] [Related]
16. Validation of modified fibrosis-4 index for predicting hepatocellular carcinoma in patients with compensated alcoholic liver cirrhosis.
Kim JH; Lee M; Park SW; Kang M; Kim M; Lee SH; Kim TS; Park JM; Choi DH
Medicine (Baltimore); 2018 Nov; 97(48):e13438. PubMed ID: 30508959
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
[TBL] [Abstract][Full Text] [Related]
18. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R
Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803
[TBL] [Abstract][Full Text] [Related]
19. Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Azuma S; Asahina Y; Kakinuma S; Azuma K; Miyoshi M; Inoue E; Tsunoda T; Sato A; Kaneko S; Nagata H; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Tomita M; Nakagawa M; Watanabe M
Dig Dis; 2019; 37(3):247-254. PubMed ID: 30625487
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Aflatoxin-Associated
Jiao J; Niu W; Wang Y; Baggerly K; Ye Y; Wu X; Davenport D; Almeda JL; Betancourt-Garcia MM; Forse RA; Stevenson HL; Watt GP; McCormick JB; Fisher-Hoch SP; Beretta L
Cancer Prev Res (Phila); 2018 Feb; 11(2):103-112. PubMed ID: 29089331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
